Effect of ulinastatin on hmgb1 expression in rats with acute lung injury induced by sepsis

Genetics and Molecular Research

Volumn 14, Issue 2, 2015, Pages 4344-4353

  Wang, S Y ^a   Li, Z J ^a   Wang, X ^a   Li, W F ^a   Lin, Z F ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Acute lung injury; High mobility group box 1; Interleukin 6; Tumor necrosis factor ; Ulinastatin

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; ULINASTATIN; GLYCOPROTEIN; HBP1 PROTEIN, RAT;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HISTOPATHOLOGY; LUNG PARENCHYMA; MALE; NONHUMAN; PROPHYLAXIS; PROTEIN EXPRESSION; RAT; SCORING SYSTEM; SEPSIS; SURVIVAL RATE; ULTRASTRUCTURE; ANIMAL; BLOOD; BRONCHOALVEOLAR LAVAGE FLUID; COMPLICATION; DRUG EFFECTS; GENE EXPRESSION; GENETICS; LUNG; METABOLISM;

RATTUS;

ACUTE LUNG INJURY; ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; GENE EXPRESSION; GLYCOPROTEINS; HMGB1 PROTEIN; INTERLEUKIN-6; LUNG; MALE; RATS; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84929484310     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2015.April.30.7     Document Type: Article

References (26)

1. Cao YZ, Tu YY, Chen X, Wang BL, et al. (2012). Protective effect of Ulinastatin against murine models of sepsis: Inhibition of TNF-α and IL-6 and augmentation of IL-10 and IL-13. Exp. Toxicol. Pathol. 64: 543-547.
2. Deng Y, Yang Z, Gao Y, Xu H, et al. (2013). Toll-like receptor 4 mediates acute lung injury induced by high mobility group box-1. PLoS One 8: e64375.
3. Entezari M, Javdan M, Antoine DJ, Morrow DM, et al. (2014). Inhibition of extracellular HMGB1 attenuates hyperoxia-induced inflammatory acute lung injury. Redox Biol. 2: 314-322.
4. Fang Y, Xu P, Gu C, Wang Y, et al. (2011). Ulinastatin improves pulmonary function in severe burn-induced acute lung injury by attenuating inflammatory response. J. Trauma 71: 1297-1304.
5. Geiser T (2003). Mechanisms of alveolar epithelial repair in acute lung injury-a translational approach. Swiss Med. Wkly. 133: 586-590.
6. Hidaka S, Iwasaka H, Hagiwara S and Noguchi T (2011). Gabexate mesilate inhibits the expression of HMGB1 in lipopolysaccharide-induced acute lung injury. J. Surg. Res. 165: 142-150.
7. Hochstrasser K, Schönberger OL, Rossmanith I and Wachter E (1981). Kunitz-type proteinase inhibitors derived by limited proteolysis of the inter-α-trypsin inhibitor, V. Attachments of carbohydrates in the human urinary trypsin inhibitor isolated by affinity chromatography. Hoppe Seylers Z. Physiol. Chem. 362: 1357-1362.
8. Ito K, Mizutani A, Kira S, Mori M, et al. (2005). Effect of ulinastatin, a human urinary trypsin inhibitor, on the oleic acid-induced acute lung injury in rats via the inhibition of activated leukocytes. Injury 36: 387-394.
9. Kim JY, Park JS, Strassheim D, Douglas I, et al. (2005). HMGB1 contributes to the development of acute lung injury after hemorrhage. Am. J. Physiol.-Lung Cell Mol. Physiol. 288: L958-L965.
10. Luan ZG, Zhang XJ, Yin XH, Ma XC, et al. (2013). Downregulation of HMGB1 protects against the development of acute lung injury after severe acute pancreatitis. Immunobiology 218: 1261-1270.
11. McLoughlin RM, Jenkins BJ, Grail D, Williams AS, et al. (2005). IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc. Natl. Acad. Sci. U. S. A. 102: 9589-9594.
12. Meduri GU, Headley S, Kohler G, Stentz F, et al. (1995). Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS plasma IL-1β and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 107: 1062-1073.
13. Nativel B, Marimoutou M, Thon-Hon VG, Gunasekaran MK, et al. (2013). Soluble HMGB1 is a novel adipokine stimulating IL-6 secretion through RAGE receptor in SW872 preadipocyte cell line: contribution to chronic inflammation in fat tissue. PLoS One 8: e76039.
14. Nishiyama T, Aibiki M and Hanaoka K (1996). The effect of ulinastatin, a human protease inhibitor, on the transfusion-induced increase of plasma polymorphonuclear granulocyte elastase. Anesth. Analg. 82: 108-112.
15. Parsons PE, Eisner MD, Thompson BT, Matthay MA, et al. (2005). Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Crit. Care Med. 33: 1-6.
16. Pietkiewicz J, Seweryn E, Bartyś A and Gamian A (2007). Receptors for advanced glycation end products and their physiological and clinical significance. Postepy Hig. Med. Dosw. 62: 511-523.
17. Razavi HM, Werhun R, Scott JA, Weicker S, et al. (2002). Effects of inhaled nitric oxide in a mouse model of sepsis-induced acute lung injury. Crit. Care Med. 30: 868-873.
18. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, et al. (2005). Incidence and outcomes of acute lung injury. N. Engl. J. Med. 353: 1685-1693.
19. Shen J, Gan Z, Zhao J, Zhang L, et al. (2012). Ulinastatin reduces pathogenesis of phosgene-induced acute lung injury in rats. Toxicol. Ind. Health. 30: 785-793
20. Silva E, Arcaroli J, He Q, Svetkauskaite D, et al. (2007). HMGB1 and LPS induce distinct patterns of gene expression and activation in neutrophils from patients with sepsis-induced acute lung injury. Intensive Care Med.. 33: 1829-1839.
21. Smith KM, Mrozek JD, Simonton SC, Bing DR, et al. (1997). Prolonged partial liquid ventilation using conventional and high-frequency ventilatory techniques: gas exchange and lung pathology in an animal model of respiratory distress syndrome. Crit.Care Med. 25: 1888-1897.
22. Sumi H, Takada Y and Takada A (1977). Studies on human urinary trypsin inhibitor 1. Its modification on treatment of urine with acid. Thromb. Res. 11: 747-754.
23. Tamaoki J, Tagaya E, Yamawaki I, Sakai N, et al. (1995). Effect of erythromycin on endotoxin-induced microvascular leakage in the rat trachea and lungs. Am. J. Respir. Crit. Care Med. 151: 1582-1588.
24. Tong Y, Tang Z, Yang T, Yang Y, et al. (2014). Ulinastatin preconditioning attenuates inflammatory reaction of hepatic ischemia reperfusion injury in rats via high mobility group box 1 (HMGB1) inhibition. Int. J. Med. Sci. 11: 337-43.
25. Wang N, Liu X, Zheng X, Cao H, et al. (2013). Ulinastatin is a novel candidate drug for sepsis and secondary acute lung injury, evidence from an optimized CLP rat model. Int. Immunopharmacol. 17: 799-807.
26. Ware LB and Matthay MA (2000). The acute respiratory distress syndrome. N. Engl. J. Med. 342: 1334-1349.